KPV: reported timelines in the literature
A research-supply summary of reported timelines for KPV (lysine-proline-valine), covering its identifiers, the pathways studied, and the timeframes reported across in vitro, animal and formulation studies.
KPV is the tripeptide lysine-proline-valine, also written Lys-Pro-Val and referred to in the literature as an endogenous tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) [2][3]. It is a short, hydrophilic peptide of three residues, and the evidence block does not supply a sequence string, molecular formula or molecular weight for it, so none are stated here. In the research literature it is handled as an anti-inflammatory and antioxidant peptide, and in formulation work it has been used as a model cargo for oral peptide delivery systems [1][2].
The mechanistic work described in the evidence centres on reactive oxygen species (ROS)-dependent signalling, specifically the AKT/mTORC1/PPARgamma axis and the PPARgamma pathway more broadly [2][3].
Research Studies
KPV and oral delivery across gastrointestinal barriers
The clearest timeline data in the evidence block come from formulation research rather than from pharmacology. A self-immolative peptide prodrug conjugate (SIPPC) platform was developed for inflammation-targeted oral delivery, combining a hydrophilic polyethylene glycol segment, a ROS-responsive hydrophobic self-immolative module, and a hydrolyzable scaffold that together assemble spontaneously into micelle-like nanoparticles [1]. KPV was one of three anti-inflammatory peptides tested alongside Ac-QAW and IRW [1].
The reported performance characteristics for the engineered conjugates were gastrointestinal stability, mucus penetration, and ROS-responsive release at the inflammation site [1]. The evidence block does not give numerical transit times, plasma half-lives or absorption percentages, so no timeline figures can be quoted for this work.
| Parameter | Reported in [1] |
|---|---|
| Delivery platform | Self-immolative peptide prodrug conjugate (SIPPC) |
| Peptides tested | KPV, Ac-QAW, IRW |
| Conjugate components | PEG segment; ROS-responsive hydrophobic self-immolative module; hydrolyzable scaffold |
| Assembly form | Micelle-like nanoparticles |
| Reported behaviours | GI stability; mucus penetration; ROS-responsive release at inflammation |
| Numerical timelines given | None stated in the evidence block |
KPV and adipogenesis in differentiating adipocytes
A study examined the regulatory effects of KPV on adipocyte differentiation in MDI-induced cells, reporting that KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARgamma signalling [2]. This is a cell-culture model, so any timeline implied by the work is a differentiation-window timeline rather than a whole-organism one. The evidence block does not state the duration of MDI induction, the treatment period, or the timepoints at which signalling was sampled, so no hour or day figures are reported here.
KPV and hepatic lipid accumulation in HepG2 cells
A separate study examined the protective role of KPV in hepatocellular steatosis, described as an early stage within the non-alcoholic fatty liver disease (NAFLD) spectrum characterised by excessive lipid accumulation and oxidative stress in hepatocytes [3]. The work reports that KPV attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARgamma pathway in HepG2 cells [3]. As with the adipocyte work, this is an in vitro system; the evidence block does not give exposure durations or sampling intervals.
| Model | Reported mechanism | Timeline data in evidence block |
|---|---|---|
| MDI-induced differentiating adipocytes [2] | ROS-mediated AKT/mTORC1/PPARgamma signalling | Not stated |
| HepG2 hepatocytes [3] | ROS-dependent regulation of PPARgamma | Not stated |
KPV in the context of host defense peptides and inflammatory bowel disease
A short review of host defense peptides (HDPs) describes them as emerging candidates for inflammatory bowel disease (IBD), a group of chronic disorders of the gastrointestinal tract causing severe inflammation and tissue damage, where current treatments often carry adverse effects [5]. The review is a field-level overview rather than a KPV-specific study, and the evidence block does not attach any timeline to KPV within it. It is included here because it frames the therapeutic area in which gastrointestinal delivery work on peptides such as KPV sits [1][5].
KPV and peptide use in sport and bodybuilding
A critical review examined the shift in pharmacological enhancement in sport from anabolic-androgenic steroids toward peptides and peptide analogues, which are marketed as more selective and ostensibly safer alternatives; the agents discussed include growth hormone secretagogues such as ipamorelin [4]. This is a review of the doping landscape, not a study of KPV, and the evidence block does not report KPV-specific findings or timelines from it. It is noted here only because it documents how peptide-class compounds are discussed outside the laboratory literature [4].
KPV and the alpha-MSH-derived tripeptide class
Two of the studies in the evidence block describe KPV in the same terms: an endogenous tripeptide derived from alpha-melanocyte-stimulating hormone, recognised for anti-inflammatory and antioxidant activities [2][3]. That shared description is the class context for the mechanism work above, and it is the reason the ROS and PPARgamma pathways recur across the adipocyte and hepatocyte studies [2][3]. No timeline is attached to the class description itself.
KPV and ROS-responsive release as a design principle
The SIPPC work treats ROS not only as a signalling node but as a release trigger: the conjugate's hydrophobic self-immolative module responds to reactive oxygen species, releasing cargo at the inflammation site [1]. This is a design property of the formulation rather than a measured pharmacokinetic timeline, and the evidence block does not quantify the release rate or lag. It is reported here because it is the one place in the evidence where a temporal behaviour — release at a site of inflammation — is explicitly described for a KPV-containing system [1].
KPV and the limits of the reported timeline evidence
Across the evidence block, no study supplies a numerical timeline for KPV: no half-life, no absorption window, no onset figure, and no sampling schedule [1][2][3][5]. The formulation study reports qualitative behaviours — GI stability, mucus penetration, ROS-responsive release — without durations [1]. The two cell studies report mechanism without exposure periods [2][3]. The reviews report field context without KPV-specific timing [4][5]. Any timeline claim for KPV beyond what is stated above would not be supported by this evidence.
If you are reading this for personal health reasons
This material is sold for laboratory research use only, and we do not provide dosing, administration or medical guidance of any kind. Nothing on this page is a recommendation for human use. If you are considering a compound for yourself, speak to a licensed clinician.
Sources
- [1] Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers — https://europepmc.org/article/PMC/PMC12802832
- [2] KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARgamma signaling — https://pubmed.ncbi.nlm.nih.gov/42585803/
- [3] Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARgamma pathway in HepG2 cells — https://pubmed.ncbi.nlm.nih.gov/42064835/
- [4] A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — https://pubmed.ncbi.nlm.nih.gov/41880199/
- [5] Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease — https://pubmed.ncbi.nlm.nih.gov/41241376/